# A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

> **NCT05627063** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Abbisko Therapeutics Co, Ltd** · enrollment: 169 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** ABSK121-NX

## Key facts

- **NCT ID:** NCT05627063
- **Lead sponsor:** Abbisko Therapeutics Co, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-26
- **Primary completion:** 2026-03-15
- **Final completion:** 2026-06-30
- **Target enrollment:** 169 (ESTIMATED)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05627063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05627063, "A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05627063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*